What Claris Lifesciences does

Claris Lifesciences (legal entity Claris Limited) is an India-based, Ahmedabad-headquartered holding company that originated in 1999 as a pharmaceutical trading business and evolved into one of India's largest pure-play sterile injectables manufacturers before divesting its core operating business. Its pre-divestiture operations spanned five manufacturing facilities (Clarion I-V) on an 80-acre campus, producing sterile injectables (ampoules, vials, large volume parenterals, emulsions), IV infusions, and Active Pharmaceutical Ingredients, with proprietary capabilities in blow-fill-seal manufacturing, aseptic filling, and lipid-based Propofol production. The company secured US FDA (2007), MHRA (2005), and European approvals, achieving 55% India market share with its Profol/Provive Propofol brand and distributing to 100+ countries.

Claris monetized its injectables business through enterprise B2B pharmaceutical manufacturing with global channel partnerships — Pfizer handled regulated-market commercialization of 15 Claris-manufactured injectables plus co-development of 48 products, while the company maintained direct presence in 76 countries by 2008 and 100+ countries by 2017 through offices in Brazil and the Philippines. A 2013 joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co. (Claris Otsuka) carved out the infusions business at a $250M valuation (3.7x turnover), and the Carlyle Group took a $20M minority stake in 2006 ahead of a Rs 300 crore BSE IPO in 2010. The Profol/Provive brand reached #1 Propofol position in India with 55% share by 2008.

Following the $625M sale of the global generic injectables business to Baxter International in 2017 and a voluntary BSE delisting in 2018 (returning Rs 1,073 crore to shareholders), Claris transitioned into 'Claris 2.0' — a venture investment and financial management holding company operating through Claris Capital (investing across HealthTech, Consumer, FinTech and Logistics), Abellon (sustainable waste-to-energy solutions for power, heat and transport), and Brihati. The current business model centers on portfolio investment returns and operating subsidiary revenues rather than pharmaceutical manufacturing.

Name

Claris Lifesciences

Legal name

Claris Limited

Website

https://clarislifesciences.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Claris Lifesciences (Claris Limited), headquartered in Ahmedabad, India, formerly operated as a pure-play sterile injectables manufacturer. Post-2017 divestiture to Baxter, it now operates as a venture investment vehicle through Claris Capital with operating subsidiaries in sustainable energy and other sectors.

Ownership category

akta.pro rank

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Sterile Injectables Manufacturing and Sales: Former core business - manufacturing and selling sterile injectable products including Propofol, IV fluids, and generic injectables globally. Products served 76 countries (2008) and 100+ countries (2017). Hit 48% growth for four consecutive years for specialty injectables business. Global generic injectables business sold to Baxter for $625m (Rs4237cr) in 2017.
2. Venture Investment and Financial Management: Post-2017 Claris 2.0 strategy focused on venture investment across HealthTech, Consumer, FinTech and Logistics sectors. Investments include Abellon Clean Energy (waste-to-energy), Brihati, and Claris Capital.
3. Joint Ventures: Claris Otsuka joint venture with Otsuka Pharmaceutical Factory and Mitsui & Co. valued at $250m (Rs1300cr). Sold stake in Claris Otsuka and exited the JV.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Claris Lifesciences (now Claris Limited) is a multi-business holding company headquartered in Ahmedabad, India. Originally a pure-play sterile injectables pharmaceutical manufacturer, the company divested its injectables business to Baxter in 2017 and currently operates as 'Claris 2.0' focused on venture investment through Claris Capital (HealthTech, Consumer, FinTech and Logistics sectors), sustainable energy solutions through Abellon, and other businesses including Brihati. The company's heritage includes advanced pharmaceutical manufacturing with blow-fill-seal technology and lipid-based Propofol production.

Product overview

Claris Lifesciences (now Claris Limited) was originally a pure play sterile injectables pharmaceutical company in India that grew to become a near billion-dollar international enterprise. The company operated as a single unified pharmaceutical manufacturing and commercialization platform with core products including sterile injectables (ampoules, vials, large volume parenterals, emulsions), IV infusions/fluids, and Active Pharmaceutical Ingredients. The company built world-class manufacturing infrastructure (Clarion I-V facilities) achieving global regulatory approvals (FDA, MHRA, European) and established strategic partnerships with Pfizer. In 2017, the core injectables business was sold to Baxter for $625m, and the company pivoted to Claris 2.0 focusing on venture investment and financial management. The current portfolio includes Claris Capital (investing in HealthTech, Consumer, FinTech and Logistics), Abellon (sustainable energy/waste-to-energy), and Brihati (business services).

Differentiator

Problem solved

Functional benefit

Brands

• Profol: Flagship injectable anesthetic product - propofol brand with 55% market share in India, also marketed as Provive internationally
• Provive
• Clarion
• Claris Otsuka

Products and services

• Claris Capital Venture investment arm that invests in and supports growth of new-age businesses across HealthTech, Consumer, FinTech and Logistics sectors, catalyzing growth through capital infusion and operational guidance.
• Abellon Clean Energy Sustainable energy solutions company providing waste-to-energy technology and solutions for Power, Heat and Transport sectors in India.
• Brihati

Quantifiable outcome

• 55% market share in India for Propofol (Profol/Provive brand)
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Abellon Clean EnergycoreStrategic or Co-development Partner · 1 January 2020Claris invests in Abellon Clean Energy - a leader in waste-to-energy in India. Part of Claris 2.0 venture investment strategy focusing on HealthTech, Consumer, FinTech and Logistics sectors.
• Baxter International Inc.flagshipStrategic or Co-development Partner · 1 January 2017Global generic injectables business sold to Baxter International Inc. (Fortune 500 American Healthcare company) for $625 million (Rs 4,237 crore). All existing debt of the company was repaid.
• Otsuka Pharmaceutical Factory, Inc.flagshipStrategic or Co-development Partner · 1 January 2013Claris Otsuka joint venture formed with Otsuka Pharmaceutical Factory (one of the biggest Japanese pharmaceutical companies) and Mitsui & Co. Ltd. 80% stake given to Japanese partners in the infusions business. Deal valued at $250 million (Rs 1,300 crore) at 3.7x turnover vs industry standard of 2x.
• Mitsui & Co. Ltd.flagshipStrategic or Co-development Partner · 1 January 2013Part of Claris Otsuka joint venture - one of the most diversified and comprehensive trading, investment and service enterprises in the world.
• PfizercoreStrategic or Co-development Partner · 1 January 2009Strategic partnership with global pharma giant Pfizer for marketing and supply of 15 Claris-manufactured sterile injectables as well as to develop 48 products for the highly regulated markets of USA, Canada, Europe, Australia and New Zealand.

Scale indicators10 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Cipla: Major Indian pharmaceutical company with global presence across generics, injectables, and respiratory therapy. Comparable as a broad Indian pharma with multinational distribution.
• Biocon: Indian biopharmaceutical company with injectables, biosimilars, and research services. Comparable as a science-driven Indian pharma with global regulatory reach.
• Dr. Reddy's Laboratories: Established Indian pharmaceutical company with global sterile injectables, generics, and biosimilars operations. Comparable in scale of regulated-market injectable footprint.
• Cadila Healthcare (Zydus): Diversified Indian pharma major with injectable, API, and biosimilar operations. Comparable in regulated-market manufacturing capability and broad therapeutic reach.
• Divi's Laboratories: Leading Indian API manufacturer serving global regulated markets. Comparable in manufacturing scale, regulatory compliance, and export-led revenue model.

Direct peers

• Gland Pharma: India-based pure-play sterile injectables manufacturer serving global regulated markets. Closest structural analogue to Claris's pre-2017 operating model.
• Strides Pharma Science: Indian pharma company with a focused sterile injectables and oral dosage business serving regulated and emerging markets, directly comparable in product portfolio and geographic mix.
• Aurobindo Pharma: Large Indian pharmaceutical manufacturer with a significant sterile injectables franchise. Directly comparable to Claris's legacy business model of regulated-market injectable manufacturing from India.
• Sequoia Capital India (Peak XV): Leading India-focused venture capital firm investing across consumer, fintech, healthtech, and logistics. Directly comparable to Claris Capital's stated investment focus under Claris 2.0.
• Accel India: Early- and growth-stage venture investor in India with focus on consumer, fintech, and healthtech. Comparable as a competing capital pool for the same sectors targeted by Claris Capital.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/clarisltd
• LinkedInlinkedin.com/company/claris-limited

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Claris Lifesciences